Nocdurna is an anti-diuretic drug owned by Ferring Pharms Inc. The active ingredient in Nocdurna is desmopressin acetate and it was first authorized for market use on 21 June, 2018. The drug comes in tablet and sublingual dosage forms. Nocdurna has a total of 10 drug patents out of which 4 have already expired.
The patents protecting Nocdurna have started to expire, with four out of ten already expired. However, the remaining patents prevent the release of generic versions of Nocdurna until 13 April, 2030. The last patent, titled 'Methods comprising desmopressin', is set to expire on this date.
Nocdurna is primarily used for the treatment of nocturia due to nocturnal polyuria in adults. It functions by regulating the amount of urine your kidneys produce. In addition, certain methods of treatment also include monitoring a patient's serum sodium concentration.
Nocdurna holds a total of ten patents. Four of these have already expired, the most recent of which being 'Pharmaceutical formulations of desmopressin' which expired on 7th May 2023. The remaining patents continue to protect Nocdurna from generic competition until 13 April, 2030, when the 'Methods comprising desmopressin' patent will expire. Below are the details of the patents: